Multivariable analysis of dCBT outcomes
| Variables∗ . | Number . | Multivariate analysis . | |
|---|---|---|---|
| HR (95% CI) . | P value . | ||
| Neutrophil recovery | |||
| Patient group | .028 | ||
| No Toci | 39 | - | |
| Toci | 45 | 0.60 (0.38-0.95) | |
| CD34+ cell dose per kg (continuous) | 84 | 1.21 (1.04-1.41) | .014 |
| Platelet recovery | |||
| Patient group | .060 | ||
| No Toci | 39 | - | |
| Toci | 45 | 1.55 (0.98-2.46) | |
| CD34+ cell dose per kg (continuous) | 84 | 1.34 (1.12-1.61) | .001 |
| Grade 2 to 4 aGVHD | |||
| Patient group | .16 | ||
| No Toci | 39 | - | |
| Toci | 45 | 0.70 (0.43-1.15) | |
| HLA match | .57 | ||
| 3-5 | 68 | - | |
| 6-7 | 16 | 1.19 (0.65-2.20) | |
| Grade 3-4 aGVHD | |||
| Patient group | .15 | ||
| No Toci | 39 | - | |
| Toci | 45 | 0.45 (0.15-1.34) | |
| HLA match | .67 | ||
| 3-5 | 68 | - | |
| 6-7 | 16 | 1.32 (0.37-4.74) | |
| TRM | |||
| Patient group | .46 | ||
| No Toci | 39 | - | |
| Toci | 45 | 1.48 (0.52-4.16) | |
| Age (continuous) | 84 | 1.03 (0.97-1.08) | .31 |
| CD34+ cell dose per kg (continuous) | 84 | 0.88 (0.56-1.37) | .57 |
| Relapse | |||
| Patient group | .11 | ||
| No Toci | 39 | - | |
| Toci | 45 | 2.56 (0.77-8.55) | |
| Diagnosis | .38 | ||
| Acute leukemia | 70 | - | |
| (AML/ALL/MPAL) | |||
| MDS/CML | 10 | 2.79 (0.73-10.6) | |
| NHL | 4 | 1.32 (0.16-10.8) | |
| HLA match | .86 | ||
| 3-5 | 68 | - | |
| 6-7 | 16 | 0.87 (0.19-4.09) | |
| PFS | |||
| Patient group | .17 | ||
| No Toci | 39 | - | |
| Toci | 45 | 1.68 (0.79-3.56) | |
| Age | 84 | 0.99 (0.96-1.03) | .65 |
| CD34+ cell dose per kg | 84 | 0.83 (0.60-1.15) | .24 |
| OS | |||
| Patient group | .17 | ||
| No Toci | 39 | - | |
| Toci | 45 | 1.86 (0.74-4.68) | |
| Age | 84 | 1.01 (0.97-1.06) | .66 |
| CD34+ cell dose/kg | 84 | 0.88 (0.60-1.30) | .51 |
| Variables∗ . | Number . | Multivariate analysis . | |
|---|---|---|---|
| HR (95% CI) . | P value . | ||
| Neutrophil recovery | |||
| Patient group | .028 | ||
| No Toci | 39 | - | |
| Toci | 45 | 0.60 (0.38-0.95) | |
| CD34+ cell dose per kg (continuous) | 84 | 1.21 (1.04-1.41) | .014 |
| Platelet recovery | |||
| Patient group | .060 | ||
| No Toci | 39 | - | |
| Toci | 45 | 1.55 (0.98-2.46) | |
| CD34+ cell dose per kg (continuous) | 84 | 1.34 (1.12-1.61) | .001 |
| Grade 2 to 4 aGVHD | |||
| Patient group | .16 | ||
| No Toci | 39 | - | |
| Toci | 45 | 0.70 (0.43-1.15) | |
| HLA match | .57 | ||
| 3-5 | 68 | - | |
| 6-7 | 16 | 1.19 (0.65-2.20) | |
| Grade 3-4 aGVHD | |||
| Patient group | .15 | ||
| No Toci | 39 | - | |
| Toci | 45 | 0.45 (0.15-1.34) | |
| HLA match | .67 | ||
| 3-5 | 68 | - | |
| 6-7 | 16 | 1.32 (0.37-4.74) | |
| TRM | |||
| Patient group | .46 | ||
| No Toci | 39 | - | |
| Toci | 45 | 1.48 (0.52-4.16) | |
| Age (continuous) | 84 | 1.03 (0.97-1.08) | .31 |
| CD34+ cell dose per kg (continuous) | 84 | 0.88 (0.56-1.37) | .57 |
| Relapse | |||
| Patient group | .11 | ||
| No Toci | 39 | - | |
| Toci | 45 | 2.56 (0.77-8.55) | |
| Diagnosis | .38 | ||
| Acute leukemia | 70 | - | |
| (AML/ALL/MPAL) | |||
| MDS/CML | 10 | 2.79 (0.73-10.6) | |
| NHL | 4 | 1.32 (0.16-10.8) | |
| HLA match | .86 | ||
| 3-5 | 68 | - | |
| 6-7 | 16 | 0.87 (0.19-4.09) | |
| PFS | |||
| Patient group | .17 | ||
| No Toci | 39 | - | |
| Toci | 45 | 1.68 (0.79-3.56) | |
| Age | 84 | 0.99 (0.96-1.03) | .65 |
| CD34+ cell dose per kg | 84 | 0.83 (0.60-1.15) | .24 |
| OS | |||
| Patient group | .17 | ||
| No Toci | 39 | - | |
| Toci | 45 | 1.86 (0.74-4.68) | |
| Age | 84 | 1.01 (0.97-1.06) | .66 |
| CD34+ cell dose/kg | 84 | 0.88 (0.60-1.30) | .51 |
HLA match and CD34+ cell dose refer to engrafted unit.